SCHEMBL544665

SCHEMBL544665

COCCNC(=O)Nc1nc2ccc(OS(=O)(=O)c3c(Cl)cccc3Cl)cc2s1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 3/20 0.58
MAPT P10636 5/20 0.56
SMN1; SMN2 Q16637 5/20 0.56
PKM P14618 1/20 0.56
GSK3A P49840 1/20 0.56
GSK3B P49841 1/20 0.56
MET P08581 2/20 0.53
CDK9 P50750 2/20 0.53
CSNK1D P48730 2/20 0.52
CASP2 P42575 1/20 0.51
ABL1 P00519 1/20 0.49
RAB9A P51151 3/20 0.49
POLB P06746 2/20 0.49
NPC1 O15118 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
SCD O00767 2/20 0.49
LMNA P02545 1/20 0.49
NFKB1 P19838 1/20 0.49
NFKB2 Q00653 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL544152 0.95 GHSR (0.53) GHSRMAPTSMN1; SMN2PKMGSK3A
SCHEMBL544153 0.89 MET (0.67) GHSRMAPTSMN1; SMN2PKMGSK3A
SCHEMBL544868 0.87 PIK3CA (0.57) GHSRMAPTSMN1; SMN2PKMGSK3A
SCHEMBL544638 0.86 GHSR (0.60) GHSRMAPTSMN1; SMN2PKMGSK3A
SCHEMBL544856 0.86 TUBB4A (0.64) GHSRMAPTSMN1; SMN2PKMGSK3A
SCHEMBL544204 0.85 ABL1 (0.58) GHSRMAPTSMN1; SMN2PKMGSK3A
SCHEMBL544033 0.84 GHSR (0.52) GHSRMAPTSMN1; SMN2PKMGSK3A
SCHEMBL543982 0.84 GHSR (0.51) GHSRMAPTSMN1; SMN2PKMGSK3A
SCHEMBL543827 0.84 GHSR (0.51) GHSRMAPTSMN1; SMN2PKMGSK3A
SCHEMBL544599 0.83 GHSR (0.55) GHSRABL1POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8110571-B2 Tyrosine kinase inhibitors; antiproliferation agents; metabolism diseases; antiallergens; central nervous system disorders; vision and skin disorders; antiarthritic agents AVENTIS PHARMA S.A. (FR) 2012-02-07 US disclosed
US-20080194555-A1 Novel Benzimidazole and Benzothiazole Derivatives, Method for Preparing Same, Use Thereof as Drugs, Pharmaceutical Compositions and Novel Use Especially as c-MET Inhibitors AVENTIS PHARMA S.A. (FR) 2008-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194555-A1 Novel Benzimidazole and Benzothiazole Derivatives, Method for Preparing Same, Use Thereof as Drugs, Pharmaceutical Compositions and Novel Use Especially as c-MET Inhibitors MET, KIT, MERTK GHSR 1821/4885MAPT 1307/4885SMN1; SMN2 4373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.